# Capgemini (Netherlands)

**Type:** Institutions  
**Canonical URL:** https://scholariq.org/institutions/capgemini-netherlands/

## Facts

| Field | Value |
| --- | --- |
| Avg h-index | 43 |
| Citations | 25,462 |
| City | Utrecht |
| Country | NL |
| Description | Capgemini (Netherlands) is a research organisation in Utrecht, NL. OpenAlex records 2,393 works and 25,462 citations for it. 987 researchers list it as their most recent affiliation. |
| Homepage | https://www.nl.capgemini.com/ |
| OpenAlex ID | https://openalex.org/I18850439 |
| Researchers | 987 |
| ROR ID | https://ror.org/03amxdk57 |
| Type | company |
| Wikidata ID | https://www.wikidata.org/wiki/Q1034621 |
| Works | 2,393 |

## University papers

- [Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update](https://scholariq.org/papers/estrogen-and-progesterone-receptor-testing-in-breast-cancer-asco-cap-guideline/)
- [Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer](https://scholariq.org/papers/effect-of-pembrolizumab-plus-neoadjuvant-chemotherapy-on-pathologic-complete/)
- [Adaptive Randomization of Veliparib–Carboplatin Treatment in Breast Cancer](https://scholariq.org/papers/adaptive-randomization-of-veliparib-carboplatin-treatment-in-breast-cancer/)
- [Adaptive Randomization of Neratinib in Early Breast Cancer](https://scholariq.org/papers/adaptive-randomization-of-neratinib-in-early-breast-cancer/)
- [Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial](https://scholariq.org/papers/durvalumab-with-olaparib-and-paclitaxel-for-high-risk-her2-negative-stage-ii-iii/)
- [Clinical Practice Guidelines on the Use of Integrative Therapies as Supportive Care in Patients Treated for Breast Cancer](https://scholariq.org/papers/clinical-practice-guidelines-on-the-use-of-integrative-therapies-as-supportive/)
- [Association of Event-Free and Distant Recurrence–Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer](https://scholariq.org/papers/association-of-event-free-and-distant-recurrence-free-survival-with-individual/)
- [Pembrolizumab plus standard neoadjuvant therapy for high-risk breast cancer (BC): Results from I-SPY 2.](https://scholariq.org/papers/pembrolizumab-plus-standard-neoadjuvant-therapy-for-high-risk-breast-cancer-bc/)

## University top topics

Showing 8 of 23.

- [Astronomy and Astrophysical Research](https://scholariq.org/topics/astronomy-and-astrophysical-research/)
- [Stellar, planetary, and galactic studies](https://scholariq.org/topics/stellar-planetary-and-galactic-studies/)
- [Business Process Modeling and Analysis](https://scholariq.org/topics/business-process-modeling-and-analysis/)
- [Ethics and Social Impacts of AI](https://scholariq.org/topics/ethics-and-social-impacts-of-ai/)
- [Information Technology Governance and Strategy](https://scholariq.org/topics/information-technology-governance-and-strategy/)
- [Big Data and Business Intelligence](https://scholariq.org/topics/big-data-and-business-intelligence/)
- [Service-Oriented Architecture and Web Services](https://scholariq.org/topics/service-oriented-architecture-and-web-services/)
- [Artificial Intelligence in Healthcare and Education](https://scholariq.org/topics/artificial-intelligence-in-healthcare-and-education/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.